Results 21 to 30 of about 5,422 (196)
Persistent isolated hypocortisolism following brief treatment with trilostane [PDF]
, 2008 A 12-year-old male neutered Miniature Poodle with confirmed pituitary-dependent hyperadrenocorticism was treated with trilostane. After three doses, it developed clinical and laboratory changes suggestive of isolated hypocortisolism ('atypical ...
Barker +19 more
core +1 more source
Frontiers in Endocrinology, 2023 ObjectiveHypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied.
Andrea Delbarba +10 more
doaj +1 more source
, 2010 Over the last 10 years, trilostane, a competitive inhibitor of steroid synthesis, is being widely used for the treatment of canine hyperadrenocorticism.
Alenza +59 more
core +1 more source
Dyslipidemia causes overestimation of plasma mitotane measurements
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Mitotane (o,p′-DDD) is the standard treatment for advanced adrenocortical carcinoma (ACC). Monitoring of plasma mitotane levels is recommended to look for a therapeutic window between 14 and 20mg/L, but its positive predictive value requires optimization.
Angelo Paci +13 more
doaj +1 more source
Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma
Endocrinology, Diabetes & Metabolism Case Reports, 2023 Mitotane is used for treatment of advanced adrenocortical carcinoma. It is administered when the carcinoma is unresectable, metastasized, or at high-risk of recurrence after resection.
Sandra Martens, Bruno Lapauw
doaj +1 more source
Conventional and novel strategies in the treatment of adrenocortical cancer
Brazilian Journal of Medical and Biological Research, 2000 Adrenocortical carcinoma is a highly malignant neoplasm with an incidence of two per million people per year. Several treatment strategies have resulted in temporary or partial tumor regression but very few cases have attained long survival.
D.E. Schteingart
doaj +1 more source
Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)
Xiehe Yixue Zazhi, 2021 Adrenocortical carcinoma (ACC) is a rare malignant tumor that occurs in the adrenal cortex, and surgery is the first choice for treating ACC. Medical therapy and radiotherapy are adjuvant treatments for patients with unresectable metastasized tumors or ...
Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital
doaj +1 more source
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome [PDF]
, 2019 When hypertension, a pathology that is frequently found in the general population, presents in a young patient, secondary causes such as Cushing's syndrome (CS), a rare disease characterized by long-term elevated cortisol levels, should be considered ...
Barbot, Mattia +2 more
core +1 more source
Frontiers in Oncology, 2023 Adrenocortical carcinoma (ACC) is a rare, heterogeneous, and aggressive malignancy with a generally poor prognosis. Surgical resection is the optimal treatment plan.
Jianhua Deng +4 more
doaj +1 more source
Medical treatment of Cushing's syndrome: Adrenal-blocking drugs and ketaconazole [PDF]
, 2010 Cushing's syndrome is associated with serious morbidity and increased mortality. Irrespective of its cause, i.e. a pituitary adenoma, ectopic ACTH production or an adrenal neoplasia, Cushing's syndrome is primarily treated surgically.
Feelders, R.A. (Richard) +2 more
core +4 more sources